Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
45 participants
INTERVENTIONAL
2023-09-01
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke
NCT01656785
Acute Stroke Thrombectomy: Does CT Perfusion Accurately Predict Infarct on MRI After Recanalization
NCT02988492
Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke
NCT02184936
Post-stroke Triage "DOC": Simple Screening for Depression, Obstructive Sleep Apnea and Cognitive Impairment
NCT02007265
Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study
NCT06100718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intensive Cancer Screening
Usual care plus FDG PET/CT
FDG PET/CT
F-fluorodeoxyglucose positron emission/computed tomography
Usual Care
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)
Usual Care
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FDG PET/CT
F-fluorodeoxyglucose positron emission/computed tomography
Usual Care
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
* patient or delegate willing and able to provide informed consent.
Exclusion Criteria
* active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brain Canada
OTHER
Heart and Stroke Foundation of Canada
OTHER
Canadian Stroke Consortium (CSC)
OTHER
Ottawa Hospital Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dariush Dowlatshahi, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Ottawa Hospital Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ottawa Hospital
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20230006-01H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.